Analyst Price Targets — DMRA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 30, 2026 12:30 pm | — | Wedbush | $40.00 | $29.18 | TheFly | Damora Therapeutics price target raised to $40 from $35 at Wedbush |
| July 26, 2026 9:17 pm | — | Jefferies | $50.00 | $28.82 | TheFly | Damora Therapeutics initiated with a Buy at Jefferies |
| June 11, 2026 10:01 am | Mitchell Kapoor | H.C. Wainwright | $45.00 | $20.15 | TheFly | Damora Therapeutics initiated with a Buy at H.C. Wainwright |
| May 28, 2026 11:02 am | David Nierengarten | Wedbush | $35.00 | $25.21 | TheFly | Damora Therapeutics initiated with an Outperform at Wedbush |
| April 23, 2026 8:20 pm | — | RBC Capital | $40.00 | $25.42 | TheFly | Damora Therapeutics initiated with an Outperform at RBC Capital |
Latest News for DMRA
Damora Therapeutics is advancing a differentiated portfolio targeting mutant calreticulin (mutCALR) in ET and MF, with three escalating mechanism programs. DMRA's lead candidate, DMR-001, offers up to 30x potency and 5x half-life over comparators, supporting convenient monthly subcutaneous dosing. CLARITY-101 trial design accelerates clinical evaluation, with proof-of-concept data expected mid-2027 and Phase 3…
-- DMR-001 is a highly potent, long-acting antibody therapy targeting Type 1 and non-Type 1 mutant calreticulin (mutCALR), designed for convenient once-monthly subcutaneous dosing -- -- In preclinical studies, DMR-001 demonstrated up to 30-fold greater potency and an approximately five-fold longer half-life than a reference anti-mutCALR antibody, supporting its best-in-class potential -- WALTHAM, Mass., Aug. 05,…
BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to six newly-hired, non-executive employees on August 1, 2026. The inducement grants were approved by Damora's independent Compensation Committee of its Board of Directors and were…
BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (Damora or the Company) (NASDAQ: DMRA), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced the completion of the redomestication of the Company from the State of Delaware to the Cayman Islands, effective on July 16, 2026. Each outstanding share of the Delaware Company's common stock…
BOSTON, July 01, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to nine newly-hired, non-executive employees on July 1, 2026. The inducement grants were approved by Damora's independent Compensation Committee of its Board of Directors and were…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for DMRA.
U.S. House Trading
No House trades found for DMRA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.